A synergistic fixed-dose combination therapy for acute diarrhea, combining an antisecretory agent (Racecadotril) with a probiotic (Saccharomyces boulardii). Racecadotril is a prodrug of thiorphan, an enkephalinase inhibitor, which reduces hypersecretion of water and electrolytes into the intestinal lumen without affecting intestinal motility. Saccharomyces boulardii is a non-pathogenic, thermophilic yeast probiotic that restores gut flora, inhibits pathogen adhesion, produces anti-toxin effects, and modulates the immune response. This combination addresses both the underlying pathophysiology and the microbial dysbiosis associated with acute diarrhea, particularly relevant in the Indian context of infectious gastroenteritis.
Adult: One sachet/capsule (Racecadotril 15mg + S. boulardii 2.5B cells) three times daily. Continue for 24-48 hours after the first normal stool, but total treatment should not exceed 7 days.
Note: Take with or without food. For sachets: Mix the granules in a glass of cool or room temperature water, milk, or formula (for infants). Do not mix with hot liquids. Stir and drink immediately. For capsules: Swallow whole with water. Do not crush or chew. Maintain adequate oral rehydration with ORS simultaneously.
Racecadotril acts as a prodrug, hydrolyzed to thiorphan, a potent enkephalinase inhibitor. This inhibition prevents the degradation of endogenous enkephalins in the intestinal mucosa. Enkephalins then activate delta-opioid receptors, leading to a reduction in cAMP and subsequent inhibition of hypersecretion of water and electrolytes into the gut lumen. It does not affect intestinal motility. Saccharomyces boulardii acts via multiple mechanisms: 1) Direct antagonism against pathogens (E. coli, Salmonella, Candida albicans, C. difficile) by competing for adhesion sites. 2) Production of a protease that degrades C. difficile toxins A and B and bacterial endotoxins. 3) Immunomodulation by stimulating secretory IgA and modulating cytokine production. 4) Trophic effects on the intestinal mucosa by increasing brush border enzyme activity (sucrase, maltase, lactase).
Pregnancy: Category C (US FDA). Animal studies are insufficient. Use only if clearly needed and potential benefit justifies potential risk to the fetus. Preferably avoid in first trimester. Safer alternatives like ORS and electrolyte management are first-line.
Driving: Unlikely to affect driving ability. However, if dizziness or headache occurs as a side effect, caution is advised.
| ACE Inhibitors (e.g., Enalapril, Ramipril) | Increased risk of angioedema due to shared pathway (inhibition of kininase II, which is similar to enkephalinase). | Major |
| Antifungals (Fluconazole, Itraconazole, Amphotericin B) | Reduced efficacy of Saccharomyces boulardii as it is a live yeast. | Moderate |
| Antibiotics (especially broad-spectrum) | Concurrent use is common for infectious diarrhea. S. boulardii is resistant to most antibiotics (except antifungals) and can prevent antibiotic-associated diarrhea. No significant interaction with racecadotril. | Minor |
| Antidiarrheals that reduce motility (Loperamide, Diphenoxylate) | Concomitant use not recommended as it may increase risk of distension or ileus. Racecadotril does not affect motility. | Moderate |
| Immunosuppressants (Cyclosporine, Tacrolimus, Chemotherapy) | Increased risk of S. boulardii fungemia. Contraindicated in severely immunocompromised. | Major |
Same composition (Racecadotril (15mg) + Saccharomyces boulardii (2.5Billion cells)), different brands: